objective To assess the prevalence of metabolic syndrome (MetS) among patients in rural Lesotho who are taking first-line antiretroviral therapy (ART) containing either zidovudine or tenofovir disoproxil.
Introduction
Antiretroviral therapy (ART) has turned formerly fatal HIV/AIDS into a chronic, manageable condition, resulting in nearly normal life expectancies for people living with HIV and AIDS (PLWHA) [1] . However, while ART massively reduces the risk of AIDS-defining conditions, such as opportunistic infections, PLWHA are at increased risk of developing non-communicable diseases (NCD) as consequence of HIV-related inflammation, hypercoagulation or antiretroviral drug toxicity [1, 2] .
Metabolic syndrome (MetS) is an interaction of various factors that directly increase the risk of cardiovascular disease and type 2 diabetes mellitus [3, 4] . Main components of MetS are abdominal obesity, dyslipidaemia, elevation of arterial blood pressure and dysregulated glucose homoeostasis [5] . HIV and ART have been shown to be associated with dyslipidaemia [6] and diabetes mellitus [7] , both of which contribute to MetS. Reported prevalence of MetS in PLWHA in high-income countries ranges from 11.2% to 45.4% [8] . In sub-Saharan Africa, the impressive scale-up of ART coverage over the last decade has lowered AIDS-related mortality and increased life expectancy for PLWHA [9] . According to UNAIDS, in 2013, an estimated 1.5 Mio PLWHA aged 50 years and older lived in Southern Africa [10] . This demographic shift among persons infected with HIV makes prevention and management of NCDs, such as MetS, a priority [11, 12] .
Nevertheless, there are very few published studies from sub-Saharan Africa assessing lipid profiles and MetS among patients on ART. Moreover, published data are mostly derived from patient cohorts receiving stavudine (D4T) or zidovudine (AZT), both older thymidine analogue nucleoside reverse transcriptase inhibitors (NRTIs). Due to better tolerability, the World Health Organization (WHO) recommends tenofovir disoproxil (TDF) as preferred first-line NRTI since 2013 [13] . As a result, D4T -known for its unfavourable effects on lipid profile [14] -has been phased out in most countries. In 2014, about 38% and 62% of adult first-line regimens in low-and middle-income countries contained AZT or TDF, respectively [15] . Studies in Europe demonstrated that replacing stavudine by tenofovir results in more favourable lipid profiles [16] . To our knowledge, there is only one small single-centre study reporting on lipid profiles and prevalence of MetS among patients receiving tenofovir or zidovudine as part of first-line ART in sub-Saharan Africa [17] .
The CART-1 study is a registered observational study assessing comorbidities and virological outcomes among patients on first-line ART in rural Lesotho, Southern Africa. In this article, we present and compare the prevalence of MetS among adult patients receiving zidovudineor tenofovir-containing first-line ART.
Methods

Study design
The study on comorbidities and virological outcomes among patients on ART (CART-1 study) is a registered observational study conducted in 10 clinics of two districts in rural Lesotho (www.clinicaltrials.gov, NCT02126696). It includes broad cross-sectional comorbidity screening among patients on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART. This analysis reports on the prevalence of MetS among study participants aged 16 years and older who were taking AZT/lamivudine (3TC) or TDF/3TC plus an NNRTI -either efavirenz (EFV) or nevirapine (NVP) -as first-line regimen.
Study setting
The comorbidity screening was conducted in May and June 2014 in two hospitals and eight health centres in Butha-Buthe and Thaba-Tseka districts. The setting has been described previously [18] . Consenting adult (≥16 years) patients on ART, attending the clinic for regular follow-up visit in a fasting state, were eligible if they were taking NNRTI-based first-line ART for at least 6 months. Clinic-employed lay counsellors interviewed participants on socio-demographic characteristics. Thereafter, participants attended their regular follow-up visits during which the nurse collected clinical parameters such as weight, height and blood pressure. Depending on the facility, blood was taken either by the nurse or by a phlebotomist at the laboratory. Except for viral load measurement, all analyses were conducted at the two hospital laboratories, both nationally certified and audited laboratories. Blood samples collected at the health centres were analysed on the same day in one of the two laboratories. Lipid panels (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) and glycosylated haemoglobin (HbA1c) were measured from whole blood from EDTA tubes on Cobas â b 101 point-of-care system (Roche Diagnostics). Analyses on Cobas â were run according to the manufacturer's standard operating procedures. Since 2010, Lesotho National ART Guidelines recommend TDF as the preferred first-line option and AZT as an alternative in case of contraindications, that is impaired renal function. In daily practice in Lesotho and as recommended by previous WHO guidelines [13] , patients who are already taking AZT without obvious side effects are continued on this regimen. At the time the CART-1 study was conducted, the ratio between patients taking AZT-or TDF-containing first-line regimens was about 1:2.
Variables and data processing
For this analysis, the main outcome variable is MetS. Following the recommendations of the International Diabetes Federation (IDF), MetS was defined as central obesity (waist circumference >80 cm in women; >94 cm in men) plus two of the following: triglycerides (TG) ≥1.7 mmol/l, high-density lipoprotein cholesterol (HDL-C) <1.03 mmol/l in men or <1.29 mmol/l in women, blood pressure ≥130/85 mmHg, fasting blood glucose (FBS) ≥5.6 mmol/l [3, 5] . Because a single blood glucose measurement may lead to overestimation of impaired fasting glucose and diabetes -particularly as many of the participants had to walk long distances to attend the facility -HbA1c was measured in case of FBS≥5.6 mmol/L. In line with international guidelines, HbA1c levels 5.6-6.4% were classified as impaired fasting glucose and HbA1c levels ≥6.5% as diabetes [19] .
Secondary outcome variables were lipid profile (total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, TG), prevalence of impaired fasting glucose and diabetes. Values of the lipid panel were classified according to recommendations of WHO and the National Cholesterol Educational Program [20, 21] .
Explanatory variables considered were NRTI and NNRTI of the ART regimen as well as clinical and sociodemographic patient characteristics (Table 1) .
Participants' wealth index was assessed using the 2009 Lesotho Demographic Health Survey questionnaire [22] . The wealth index was subsequently categorised into quintiles. Variables were collected on paper-based case reporting forms. The forms were digitalised in Lesotho and subsequently processed with Data-Scan 5.7.7 (Neoptec, Montpellier, France) for electronic data capture. Prior to analysis, all data were manually cross-checked against the original records.
Statistical analysis
Prevalence of MetS is described in proportions with binomial 95% confidence intervals (95% CI). All statistical 3) in women and 6.3% (4.1-9.1) in men (P < 0.001). As shown in Table 2 low HDL-C and a total cholesterol to HDL-C ratio ≥3.0 were more frequent among female than male patients (Table 2) .
ART regimen and frequency of MetS
Prevalence of MetS was similar in the subgroups taking EFV or NVP as NNRTI. Among men, MetS prevalence was 6.3% in both subgroups. Among women, MetS prevalence in EFV and NVP subgroups was 21.1% and 24.9%, respectively (OR: 1.24; 95% CI: 0.86-1.79, P = 0.249). Table 3 shows prevalence of MetS stratified by NRTI. Prevalence of MetS in male patients taking AZT/3TC or TDF/3TC was 6.0% (95% CI: 2.4-11.9) and 6.4% (95% CI: 3.8-9.9), respectively (OR 0.93; 0.38-2.29, P = 0.881). Among women, patients on AZT/3TC had higher rates of MetS as compared to TDF/3TC (27.9% (95% CI: 22.9-33.5) vs. 18.8% (95% CI: 15.2-22.4)). In the unadjusted logistic regression, women on AZT/3TC were significantly more likely to present with MetS as compared to women taking TDF/3TC (OR 1.70 (95% CI: 1.21-2.41, P = 0.002)). Table 4 shows the results of univariate and multivariate logistic regression analysis for MetS in women and men. In female patients, age, lower school education, higher household wealth quintile, higher BMI, longer history of taking ART, a CD4 cell count <200 cells/ll, living in the district of Butha-Buthe and AZT/3TC as NRTI backbone (vs. TDF/3TC) were associated with MetS in univariate analysis. In multivariate analysis, age, lower school education, higher BMI and AZT/3TC backbone remained significantly associated with MetS (Table 4) . Taking AZT/3TC as NRTI backbone was the strongest predictor for MetS in this multivariate model (aOR 2.21 (95% CI: 1.48-3.30), P < 0.001).
In male patients, only a higher household wealth quintile and a higher BMI were associated with MetS in univariate analysis. In multivariate analysis, BMI remained the only independent variable significantly associated with MetS (Table 4) .
Discussion
This cross-sectional survey conducted in 10 facilities of two different districts in Lesotho assessed the prevalence of MetS among patients aged ≥16 years taking first-line NNRTI-based ART for 6 months or longer. Close to one in four women on first-line ART presented MetS, whereas the prevalence among men was much lower at one in 15. As a key finding of our study, taking AZT/ 3TC as NRTI backbone was strongly associated with the presence of MetS in women, but not in men.
Interpretation of these findings should be limited to patients taking NNRTI-based first-line ART≥6 months in a rural setting. A limitation of our study is that MetS was diagnosed based on a single clinical and laboratory assessment. In particular, a one-time blood pressure measurement may lead to an overestimation of the prevalence of high blood pressure [23] . Furthermore, the IDF definition of MetS is commonly used in surveys conducted in sub-Saharan Africa [17, 24, 25] . However, the exact definition of MetS remains under debate, and standards for abdominal circumference have not been established in African populations [3] . This may partly explain the higher prevalence of MetS among women in most African studies. A further limitation is the potential of a selection bias as patients were not randomly allocated to AZT/ 3TC or TDF/3TC. The multivariate logistic regression in Table 4 accounts for potential confounders. An initial selection bias at prescription of AZT or TDF can, however, not be excluded. The strengths of our study are its relatively large sample size, prospectively collected clinical, laboratory and socio-demographic data as part of a registered study, the multi-centre setting and the use of HbA1c instead of single measurement of fasting blood glucose for definition of impaired fasting glucose.
In line with other surveys among patients on ART in sub-Saharan Africa, the overall burden of MetS was high, particularly among women [24, 25] . In our study, female patients tended to have a higher prevalence in all four components of the IDF definition for MetS. The difference between women and men was most pronounced for abdominal obesity and low HDL-C (Table 2) . Hirigo et al. report a similar gender disparity in a smaller cohort in Ethiopia, where women had higher prevalence of abdominal obesity and low HDL-C [26] .
Studies assessing metabolic abnormalities among patients taking ART -or more specifically prevalence of MetS -in sub-Saharan Africa are still scare. A recently LDL, low-density lipoprotein; HDL, high-density lipoprotein. *Waist circumference female >80 cm, male ≥94 cm. †HDL female ≤1.3 mmol/L, male ≤1 mmol/L. ‡Blood glucose >5.6 mmol/L-6.9 mmol/L and HbA1c 5.6-6.4%. §Blood glucose ≥7.0 mmol/L; and HbA1c ≥6.5%.
published systematic review identified only eight studies from four countries reporting MetS prevalence among PLWHA in Africa [27] . The mean prevalence of MetS, low HDL, hypertension, abdominal obesity and high fasting blood glucose was 30.5%, 32.8%, 21.6%, 20.9% and 18.1%, respectively. Only three studies from Africa report on association between ART and MetS. Malangu reports that protease inhibitor containing ART and being on ART for more than 5 years were associated with MetS in Botswana [28] . Berhane et al. found a history of ART >12 months to be associated with MetS [29] , and Tesfaye et al. report stavudine-containing ART as a risk factor for MetS [25] . The two latter studies were conducted in Ethiopia. We found no study comparing MetS in TDF-and AZT-containing regimens in Africa.
In our study, taking AZT instead of TDF as NRTI backbone was significantly associated with MetS in women, but not in men. D4T, another thymidine analogue, was associated with unfavourable lipid profiles and MetS in several studies conducted in sub-Sahara Africa [25] . In a large cohort study conducted in Tanzania, D4T as compared to AZT was a risk factor for developing dyslipidaemia [14] . Several studies conducted in the United States and Europe report a favourable effect of TDF on lipid profiles as compared to other NRTIs [16, 30, 31] . However, to our knowledge, this is the first study on the association between AZT and MetS in African populations. A recently published single-centre study in Uganda with a sample size of 250 patients found an aOR of 1.67 for MetS in patients on AZT/3TC/NVP as compared to TDF/3TC/EFV. The finding was, however, not significant, and the analysed subgroups were small (129 in TDF and 68 in AZT group) [17] . With near-normal life expectancies among PLWHA taking ART and increasing age of patients on ART, cardio-vascular risk factors in PLWHA gain considerable importance. Despite the recommendation of the WHO to use TDF/3TC/EFV as preferred first-line regimen, nearly one-third of patients on first-line ART were still taking AZT in 2016 [15] . Our study adds evidence to the unfavourable side effect profile of AZT. In the same patient cohort, we previously described the lower rates of viral suppression under AZT-vs. TDF-containing regimens [18] . Our finding of higher rates of MetS among women taking AZT is another important point endorsing the WHO-recommended policy of TDF as the preferred NRTI backbone in first-line ART for resource-limited settings.
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